Prostate
: increased risk relative to surgery, for
10 y fu: bladder (ERR=77%), rectum
(105%), in-field sarcomas (217%), and lung (42%)
(Brenner et al. 2000)
Breast
: compared to no RT: contralateral breast (ERR=18%), soft-tissue sarcoma
(134%), lung (61%), oesophagus (106%), leukemia (71%)
(EBCTCG, Lancet 2005)
Breast
: compared to no RT: ERR= 45% for sites with D>1Gy (lung, oesophagus,
pleura, bone, soft tissue), ERR=9% for contralateral breast ca (D≈1Gy), no evidence for
enhanced risk for D<1 Gy
(Berrington de Gonzalez et al. 2010)
Cervix
: compared to general population: for all latency periods ERR(D>3Gy) >
ERR(1Gy<D<3Gy) > ERR(D<1Gy). 10-19y: 53%, 22%, 12%
(Chaturvedi, Travis, et al, 2007)
Several sites
: 85%: D
3 Gy
(Dörr and Herrmann, 2002)
Various primary tumors:
Relatively few secondary solid cancers for very low doses
29
Clinical data
Position of RT induced 2
nd
tumors relative to HIGH
DOSE AREA